Identification of Differentially Expressed Genes in Human Varicose Veins: Involvement of Matrix Gla Protein in Extracellular Matrix RemodelingCario-Toumaniantz C.a, b · Boularan C.a, b · Schurgers L.J.g · Heymann M.-F.c · Le Cunff M.a, d · Léger J.a, d, e · Loirand G.a, b, f · Pacaud P.a, b
aINSERM, U533, bUniversité de Nantes, Faculté des Sciences et Techniques, l’Institut du Thorax, cCHU Nantes, Service d’anatomo-pathologie, Hôpital Guillaume et René Laënnec, dUniversité de Nantes, Faculté de médecine, l’Institut du Thorax, eOuest-Genopôle, fCHU Nantes, l’Institut du Thorax, Nantes, France; gDepartment of Biochemistry, University of Maastricht, Maastricht, The Netherlands
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
This study was designed to identify the global pattern of differentially expressed genes in human varicose veins. Using suppressive subtractive hybridization, we identified overexpression of genes known to be associated with extracellular matrix remodeling, including collagen III, tissue inhibitor of metalloproteinases I, dermatopontin, matrix Gla protein (MGP) and tenascin C. Real-time polymerase chain reaction analysis confirmed the differential expression of these genes. The overexpression of MGP transcript was associated with increased MGP level in varicose veins, in particular the undercarboxylated form of the protein. Smooth muscle cells from varicose veins showed increased proliferation rate and enhanced matrix mineralization. This observation correlated with the presence of ectopic mineralization areas in the varicose vein walls. The use of warfarin, to inhibit MGP activity, or siRNA targeting MGP transcript induced a reduction in the exacerbated proliferation of varicose vein smooth muscle cells. Our results suggest that high expression of MGP in varicose veins may contribute to venous wall remodeling by affecting proliferation and mineralization processes probably through impaired carboxylation of MGP. In addition, suppressive subtractive hybridization results also produce a profile of differentially expressed genes in varicose veins, in particular extracellular matrix components. Further study of these genes will provide insights into their specific roles in the etiology of venous disease.
© 2007 S. Karger AG, Basel
- Evans CJ, Fowkes FG, Hajivassiliou CA, Harper DR, Ruckley CV: Epidemiology of varicose veins: a review. Int Angiol 1994;13:263–270.
- Kurtz X, Kahn SR, Abenhaim L, Clement D, Norgren L, Baccaglini U, Berard A, Cooke JP, Cornu-Thenard A, Depairon M, Dormandy JA, Durand-Zaleski I, Fowkes GR, Lamping DL, Partsch H, Scurr JH, Zuccarelli F: Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Int Angiol 1999;18:83–102.
- Adhikari A, Criqui MH, Wooll V, Denenberg JO, Fronek A, Langer RD: The epidemiology of chronic venous desease. Phlebology 2000;15:2–18.
- Venturi M, Bonavina L, Annoni F, Colombo L, Butera C, Peracchia A, Mussini E: Biochemical assay of collagen and elastin in the normal and varicose vein wall. J Surg Res 1996;60:245–248.
- Kirsch D, Dienes HP, Kuchle R, Duschner H, Wahl W, Bottger T, Junginger T: Changes in the extracellular matrix of the vein wall – the cause of primary varicosis? Vasa 2000;29:173–177.
- Travers JP, Brookes CE, Evans J, Baker DM, Kent C, Makin GS, Mayhew TM: Assessment of wall structure and composition of varicose veins with reference to collagen, elastin and smooth muscle content. Eur J Vasc Endovasc Surg 1996;11:230–237.
- Lowell RC, Gloviczki P, Miller VM: In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg 1992;16:679–686.
- Khan AA, Eid RA, Hamdi A: Structural changes in the tunica intima of varicose veins: a histopathological and ultrastructural study. Pathology 2000;32:253–257.
- Jacob MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, Michel JB: Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 2001;49:326–332.
- Cario-Toumaniantz C, Evellin S, Maury S, Baron O, Pacaud P, Loirand G: Role of Rho kinase signalling in non-varicose and varicose human saphenous veins. Br J Pharmacol 2002;137:205–212.
- Wali MA, Dewan M, Eid RA: Histopathological changes in the wall of varicose veins. Int Angiol 2003;22:188–193.
- Sansilvestri-Morel P, Nonotte I, Fournet-Bourguignon MP, Rupin A, Fabiani JN, Verbeuren TJ, Vanhoutte PM: Abnormal deposition of extracellular matrix proteins by cultured smooth muscle cells from human varicose veins. J Vasc Res 1998;35:115–123.
- Kockx MM, Knaapen MW, Bortier HE, Cromheeke KM, Boutherin-Falson O, Finet M: Vascular remodeling in varicose veins. Angiology 1998;49:871–877.
- Sansilvestrini-Morel P, Rupin A, Badier-Commander C, Kern P, Fabiani JN, Verbeuren TJ, Vanhoutte PM: Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res 2001;38:560–568.
- Wali MA, Eid RA: Changes of elastic and collagen fibers in varicose veins. Int Angiol 2002;21:337–343.
- Badier-Commander C, Verbeuren TJ, Lebard C, Michel J-B, Jacob M-P: Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 2000;192:105–112.
- Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD: Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 1996;93:6025–6030.
- Cario-Toumaniantz C, Reillaudoux G, Sauzeau V, Heutte F, Vaillant N, Finet M, Chardin P, Loirand G, Pacaud P: Modulation of RhoA-Rho kinase-mediated Ca2+ sensitization of rabbit myometrium during pregnancy – role of Rnd3. J Physiol 2003;552:403–413.
- Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, Kummer W, Bohle RM: Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998;4:1329–1333.
- Braam LAJLM, Dissel P, Gijsbers BLMG, Spronk HMH, Hamulyàk K, Soute BAM, Debie W, Vermeer C: Assay for human matrix gla protein in serum. Arterioscler Thromb Vasc Biol 2000;20:1257–1261.
- Hackeng TM, Rosing J, Spronk HMH, Vermeer C: Total chemical synthesis of human matrix Gla protein. Protein Sci 2001;10:864–870.
- Schurgers LJ, Teunissen KJF, Knapen MHJ, Kwaijtaal M, Van Diest R, Appels A, Reutelingsperger CP, Cleutjens JPM, Vermeer C: Novel conformation-specific antibodies against matrix γ-carboxyglutamic acid (Gla) protein. Arterioscler Thromb Vasc Biol 2005;25:1629–1633.
Sheehan D, Hrapchak B: Theory and Practice of Histotechnology, ed 2. Columbus, Battelle Press, 1980, pp 225–226.
- Sansilvestri-Morel P, Rupin A, Jaisson S, Fabiani JN, Verbeuren TJ, Vanhoutte PM: Synthesis of collagen is dysregulated in cultured fibroblasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells. Circulation 2002;106:479–483.
- Cario-Toumaniantz C, Loirand G, Ladoux A, Pacaud P: P2X7 receptor activation-induced contraction and lysis in human saphenous vein smooth muscle. Circ Res 1998;83:196–203.
- Canfield AE, Farrington C, Dziobon MD, Boot-Handford RP, Heagerty AM, Kumar SN, Roberts ISD: The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol 2002;196:228–234.
- Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM: Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003;23:489–494.
- Jono S, Ikari Y, Vermeers C., Dissel P, Hasegawa K, Shioi A, Taniwaki H, Kizu A, Nishizawa Y, Saito S: Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004;91:790–794.
- Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998;18:1400–1407.
- Yagami K, Suh JY, Enomoto-Iwamoto M, Koyama E, Abrams WR, Shapiro IM, Pacifici M, Iwamoto M: Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J Cell Biol 1999;147:1097–1108.
- Shanahan CM, Cary NRB, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME: Medial localization of mineralization-regulating proteins in association with Mönckeberg’s sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999;100:2168–2176.
- Canfield AE, Doherty MJ, Kelly V, Newman B, Farrington C, Grant ME, Boot-Handford RP: Matrix Gla protein is differentially expressed during the deposition of a calcified matrix by vascular pericytes. FEBS Lett 2000;487:267–271.
- Shioi A, Nishizawa Y, Jono S, Koyama H, Hosoi M, Morii H: β-Glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995;15:2003–2009.
- Poburko D, Lee CH, van Breemen C: Vascular smooth muscle mitochondria at the cross roads of Ca2+ regulation. Cell Calcium 2004;35:509–521.
- Glowinski J, Glowinski S: Generation of reactive oxygen metabolites by the varicose vein wall. Eur J Vasc Endovasc Surg 2002;23:550–555.
- Michiels C, Bouaziz N, Remacle J: Role of the endothelium and blood stasis in the development of varicose veins. Int Angiol 2002;21:18–25.
- Bouaziz N, Redon M, Quéré L, Remacle J, Michiels C: Mitochondrial respiratory chain as a new target for anti-ischemic molecules. Eur J Pharmacol 2002;441:35–45.
- Revenu C, Athman R, Robine S, Louvard D: The co-workers of actin filaments: from cell structures to signals. Nat Rev Mol Cell Biol 2004;5:635–646.
- Sansilvestrini-Morel P, Rupin A, Badier-Commander C, Fabiani JN, Verbeuren TJ: Chronic venous insufficiency: dysregulation of collagen synthesis. Angiology 2003;54:S13–S18.
- Sansilvestrini-Morel P, Rupin A, Jullien ND, Lembrez N, Mestries-Dubois P, Fabiani JN, Verbeuren TJ: Decreased production of collagen type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP-3. J Vasc Res 2005;42:388–398.
- Takeda U, Utani A, Wu J, Adachi E, Koseki H, Taniguchi M, Matsumoto T, Ohashi T, Sato M, Shinkai H: Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. J Invest Dermatol 2002;119:678–683.
- Hsia HC, Schwarzbauer ES: Meet the tenascins: multifunctional and mysterious. J Biol Chem 2005;280:26641–26644.
- Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 1997;386:78–81.
- Melaragno MG, Fridell YW, Berk BC: The Gas6/Axl system: a novel regulator of vascular cell function. Trends Cardiovasc Med 1999;9:250–253.
- Son BK, Kozaki K, Iijima K, Eto M, Kojima T, Ota H, Senda Y, Maemura K, Nakano T, Akishita M, Ouchi Y: Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 2006;98:1024–1031.
- Son BK, Kozaki K, Iijima K, Eto M, Nakano T, Akishita M, Ouchi Y: Gas6/Axl-PI3K/Akt pathway plays a central role in the effect of statins on inorganic phosphate-induced calcification of vascular smooth muscle cells. Eur J Pharmacol 2007;556:1–8.
- Shanahan CM, Cary NRB, Metcalfe JC, Weissberg PL: High expression of genes for calcification-regulation proteins in human atherosclerotic plaques. J Clin Invest 1994;93:2393–2402.
- Dhore CR, Cleutjens JPM, Lutgens E, Cleutjens KBJM, Geussens P, Kitslaar PJEHM, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ: Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998–2003.
- Spronk HMH, Soute BAM, Schurgers LJ, Cleutjens JPM, Thijssen HHW, De Mey JGR, Vermeer C: Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 2001;289:485–490.
- Sakata N, Takeuchi K, Noda K, Saku K, Tachikawa Y, Tashiro T, Nagai R, Horiuchi S: Calcification of the medial layer of the internal thoracic artery in diabetic patients: relevance of glycoxidation. J Vasc Res 2003;40:567–574.
- Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004;95:560–567.
- Schürgers LJ, Teunissen KJF, Knapen MHJ, Kwaijtaal M, Van Diest R, Appels A, Reutelingsperger CP, Cleutjens JPM, Vermeer C: Novel conformation-specific antibodies against matrix γ-carboxyglutamic acid (Gla) protein. Arterioscler Thromb Vasc Biol 2005;25:1629–1633.
- Price PA, Faus SA, Williamson MK: Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000;20:317–327.
- Sweatt A, Sane DC, Hutson SM, Wallin R: Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003;1:178–185.
- Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16:2920–2930.
- Julien M, Magne D, Masson M, Rolli-Derkinderen M, Chassande O, Cario-Toumaniantz C, Cherel Y, Weiss P, Guicheux J: Phosphate stimulates matrix Gla protein expression in chondrocytes through the extracellular signal regulated kinase signaling pathway. Endocrinology 2007;148:530–537.
- Newman B, Gigout LI, Sudre L, Grant ME, Wallis GA: Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival. J Cell Biol 2001;154:659–666.
- Bostrom K, Zebboudj AF, Yao Y, Lin TS, Torres A: Matrix Gla protein stimulates VEGF expression through increased transforming growth factor-β1 activity in endothelial cells. J Biol Chem 2004;279:52904–52913.
- Urbanek T, Skop B, Wiaderkiewicz R, Wilczok T, Ziaja K, Lebda-Wyborny T, Pawlicki K: Smooth muscle cell apoptosis in primary varicose veins. Eur J Vasc Endovasc Surg 2004;28:600–611.
- Ducasse E, Giannakakis K, Chevalier J, Dasnoy D, Puppinck P, Speziale F, Fiorani P, Faraggiana T: Dysregulated apoptosis in primary varicose veins. Eur J Vasc Endovasc Surg 2005;29:316–323.
- Hruska KA, Mathew S, Saab G: Bone morphogenetic proteins in vascular calcification. Circ Res 2005;97:105–114.
- Zebboudj AF, Imura M, Bostrom K: Matrix Gla protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002;277:4388–4394.
- Li JM, Fan LM, Shah A, Brooks G: Targeting αvβ3 and α5β1 for gene delivery to proliferating VSMCs: synergistic effect of TGF-β1. Am J Physiol 2003;285:H1123–H1131.
- Sajid M, Zhao R, Pathak A, Smyth SS, Stouffer GA: αvβ3-integrin antagonists inhibit thrombin-induced proliferation and focal adhesion formation in smooth muscle cells. Am J Physiol 2003;285:C1330–C1338.
- Nishimoto SK, Nishimoto M: Matrix Gla protein C-terminal region binds to vitronectin: co-localization suggests binding occurs during tissue development. Matrix Biol 2005;24:353–361.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.